Results 91 to 100 of about 1,950 (155)

Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men

Aims/hypothesis: Hypoxia-inducible factor prolyl 4-hydroxylase (HIF-P4H) enzymes regulate adaptive cellular responses to low oxygen concentrations. Inhibition of HIF-P4Hs leads to stabilisation of hypoxia-inducible factors (HIFs) and activation of the ...
Koivunen, Peppi, Koistinen, Heikki A, Mäkinen, Selina, Kultalahti, Henric, Sree, Sreesha, Koistinen, Heikki A., Ala-Nisula, Tuulia   +6 more
core   +1 more source

Roxadustat and transfusional iron overload induced hypothyroidism in a hemodialysis patient: a case report with a literature review

Renal Replacement Therapy
Background Although roxadustat has been reported to cause central hypothyroidism, the details of the mechanisms and clinical characteristics of patients who are prone to developing hypothyroidism with roxadustat are uncertain. Case presentation A 53-year-
Chikako Yamashita, Yuri Hirai, Toshiya Nishigaito, Kensuke Mitsumoto, Aya Mizumoto, Manabu Kawakami, Takashi Uzu   +6 more
doaj   +1 more source

Roxadustat-induced central hypothyroidism in hemodialysis patients: a report of two cases

Neike lilun yu shijian
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of oral medications for treating renal anemia, but adverse drug events have been reported both in China and internationally in recent years.
Yumiao XIA, Peng FU, Hao WU
doaj   +1 more source

Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat

Key Clinical Message Recently, hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors have been used for renal anemia, but side effects have also been reported.
Mizuki Hayashi, Hitoshi Yokoyama, Serina Kita, Kengo Furuichi, Keiji Fujimoto, Toshitaka Sawamura, Hiroshi Okuyama, Atsushi Nakagawa, Takaya Kondo, Shinichiro Nakao   +9 more
core   +1 more source

Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats

BMC Nephrology
Background Roxadustat is a novel hypoxia- inducible factor-prolyl hydroxylase inhibitor(HIF-PHI) used to treat anemia in chronic kidney disease (CKD) patients.
Zhaoli Gao, Yanxia Gao, Qiang Wang, Qi Wang, Peng Lu, Hailin Lv, Haoran Xue, Xiaotian Ma, Shuen Li, Zhao Hu   +9 more
doaj   +1 more source

Stabilization of HIF-1α using the prolyl hydroxylase inhibitor roxadustat reduces gastrointestinal graft-versus-host disease

Scientific Reports
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for high-risk hematologic malignancies, yet its efficacy is limited by the onset of graft-versus-host disease (GVHD).
Vasantharaja Raguraman, Shanid Mohiyuddin, Tyler Plank, Catherine Benge, Linnea Banker, Richard D. Hammer, Senthilnathan Palaniyandi, Gerhard C. Hildebrandt   +7 more
doaj   +1 more source

Clinical characteristics and influencing factors of roxadustat-induced central hypothyroidism in patients receiving peritoneal dialysis

Background This study aimed to investigate the clinical characteristics and risk factors of central hypothyroidism (CEH) in peritoneal dialysis (PD) patients treated with roxadustat.
Xiaoying Ren, Mei Wang, Yuhui Lin, Qinghua Yang, Jiaxiang Ding   +4 more
core   +1 more source

HIF-PH Inhibitor Promotes Stabilization of HIF-1α via Inhibition of Its Degradation and Exerts Chondroprotective Effects in a Rat Osteoarthritis Model. [PDF]

Int J Mol Sci
Nakamura K, Fujii Y, Arai Y, Nakagawa S, Inoue A, Cha R, Sugie K, Hayashi K, Saito T, Kishida T, Mazda O, Takahashi K.   +11 more
europepmc   +1 more source

Dose Conversion Ratio Between Roxadustat and Daprodustat in Patients With Non-dialysis Chronic Kidney Disease. [PDF]

Cureus
Hirai K, Morino J, Yanai K, Mutsuyoshi Y, Kitano T, Miyazawa H, Ito K, Masuda T, Ookawara S, Morishita Y.   +9 more
europepmc   +1 more source

Comparative efficacy and safety of methoxy polyethylene glycol-epoetin beta and roxadustat in the management of renal anemia in maintenance hemodialysis. [PDF]

Front Pharmacol
Tang HE, Qiu YE, Ge RX, Lin XJ, Zhao Q, Liu Q.   +5 more
europepmc   +1 more source